https://www.avient.com/news/polyone-announces-strong-fourth-quarter-and-full-year-2013-results
Gain on sale of business
Business acquisitions, net of cash acquired
Proceeds from sale of businesses and other assets
https://www.avient.com/investor-center/news/avient-announces-fourth-quarter-and-full-year-2023-results
Taxes paid on gain on sale of business
Business Segment Operations (Unaudited)
Taxes paid on gain on sale of business
https://www.avient.com/sites/default/files/2025-01/Securities Trading Policy %282024%29 Final.pdf
Information should not be regarded as “public” until at least 24
hours after it has been published by a national news medium or has otherwise become
available through an official news release or official announcement.
4.
You may not disclose it to
others, such as family members, other relatives, or business or social acquaintances.
Trading Bans: From time to time, the Company, through the General Counsel, may
prohibit trading during a time other than during a blackout period in light of
developments that could involve material nonpublic information.
https://www.avient.com/sites/default/files/2023-03/Avient Annual Report 2022.pdf
We have developed key recruitment and retention strategies, objectives and measures that guide our human capital
management approach as part of the overall management of our business.
Business
Development Manager, Color and Additives Asia, February 2010 to January 2011.
Bank Trust Company, National Association
(as successor in interest to U.S.
https://www.avient.com/investor-center/news/polyone-announces-first-quarter-2020-results
Factors that could cause actual results to differ materially from those implied by these forward-looking statements include the impact the COVID-19 pandemic has on our business, results from operations, financial condition and liquidity; the time required to consummate the acquisition of Clariant's color and additive masterbatch business; the satisfaction or waiver of conditions in the purchase agreements; any material adverse changes in Clariant's color and additive masterbatch business; the ability to obtain required regulatory or other third-party approvals and consents and otherwise consummate the proposed acquisition of Clariant's color and additive masterbatch business; our ability to achieve the strategic and other objectives relating to the proposed acquisition of Clariant's color and additive masterbatch business, including any expected synergies; our ability to successfully integrate Clariant's color and additive masterbatch business and achieve the expected results of the acquisition of Clariant's color and additive masterbatch business, including, without limitation, the acquisition being accretive; disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; changes in polymer consumption growth rates and laws and regulations regarding plastics in jurisdictions where we conduct business; changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; fluctuations in raw material prices, quality and supply, and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to raise or sustain prices for products or services; an ability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to acquisitions and integration, working capital reductions, costs reductions and employee productivity goals; information systems failures and cyberattacks; and other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation.
Business acquisitions, net of cash acquired
Business Segment Operations (Unaudited)
https://www.avient.com/sites/default/files/2020-10/antimicrobial-dental-case-study.pdf
SOLVING PRODUCTION BOTTLENECKS WITH
A CUSTOMIZED ADDITIVE FORMULATION
© 2020, All Rights Reserved
Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012
To learn more about WithStand
Antimicrobials, contact Avient at
+1.844.4AVIENT (1.844.428.4368)
THE CHALLENGE
A well-known manufacturer of private label
toothbrushes and dental care products for national
drug store chains was experiencing several production
problems in its molding operations.
THE IMPACT
Avient was able to reduce lead time on these newly
developed additives by a week versus the original
supplier, enabling this customer to better manage
and control inventory levels.
WithStand Antimicrobial Additives provide a proven,
effective, durable, uncompromised solution to limit
microbe development in finished plastic devices.
https://www.avient.com/sites/default/files/2023-05/SG Liner for Pipe Replacement - Case Study.pdf
But using existing energy infrastructure to
deliver these sources, especially among nations that
have relied on traditional energy sources for centuries,
has limitations.
To help address these challenges, Avient teamed up
with a leading technology development company.
THE SOLUTION
Avient worked with the company to develop a novel
reinforcement material comprised of Avient Fiber-Line™
carbon fiber tows in which the filaments were manipulated
to increase strength and improve abrasion resistance.
https://www.avient.com/sites/default/files/2022-03/Avient 2021 Annual Report.pdf
BUSINESS
Business Overview
specialized developer and manufacturer of performance enhancing additives, liquid colorants and fluoropolymer and
silicone colorants.
Business Development Manager, Color and Additives Asia, 2010 to 2011.
Our Business
specialized developer and manufacturer of performance enhancing additives, liquid colorants and fluoropolymer and
silicone colorants.
https://www.avient.com/sites/default/files/2024-07/TPE Whitepaper_0.pdf
You
may recognize the two healthcare megatrends
that are driving global demand for pharmaceutical
packaging, medical devices and drug delivery
devices: economic gains in developing nations and
an aging global population that requires treatment
for chronic conditions.
The necessary increase in efficiencies has pushed
optimization efforts into every facet of product
development and distribution—from supply chain
through production.
You have an opportunity to drive growth by addressing global demand
for your products, which is spiking in direct response to the needs of
elderly patients and the increasing number of middle-class consumers
in China, India and Brazil, among other nations.
https://www.avient.com/sites/default/files/resources/PolyOne%25202014%2520Annual%2520Report.pdf
Research and Development
We have substantial technology and development capabilities.
We operate research and development centers that support our commercial development
activities and manufacturing operations.
POWELL
Retired Chairman and Chief
Executive Officer, National Starch
and Chemical Company
Committee: 2*
KERRY J.